Sign In
Buy ALC
$64.22
-0.0600 (-0.0933%)
At Close: Jun 03, 2026
Is it Apt to Retain Alcon Stock in Your Portfolio for Now?
09:21am, Wednesday, 02'nd Jul 2025
ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.
Alcon Canada Earns Global Recognition as a Top Employer
09:03am, Thursday, 26'th Jun 2025
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Can
Gordon Schanzlin New Vision Institute Becomes First U.S. Clinic to Use Alcon's Breakthrough Unity Phaco System
10:00am, Wednesday, 25'th Jun 2025
Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification Advancement in Over 15 Years Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
09:02am, Friday, 20'th Jun 2025
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intr
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of L
Alcon Stock Rises Following the FDA Approval of TRYPTYR
10:36am, Thursday, 29'th May 2025
FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.
US FDA approves Alcon's new dry-eye drug
05:47pm, Wednesday, 28'th May 2025
Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).
GENEVA--(BUSINESS WIRE)--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease.
The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand f
Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript
12:03pm, Wednesday, 14'th May 2025
Alcon Inc. (NYSE:ALC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stone
Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered
09:51am, Wednesday, 14'th May 2025
ALC ends the first quarter of 2025 on a disappointing note.
Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
08:13am, Wednesday, 14'th May 2025
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.
Alcon (ALC) Reports Q1 Earnings: What Key Metrics Have to Say
07:01pm, Tuesday, 13'th May 2025
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates a
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
04:30pm, Tuesday, 13'th May 2025
GENEVA--(BUSINESS WIRE)--Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS.
Ahead of Alcon (ALC) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:20am, Thursday, 08'th May 2025
Evaluate the expected performance of Alcon (ALC) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for b
